Oncostellae 

Developing safer, GI-targeted treatments in IBD and Colorectal cancer

OWNER

Guido Kurz (See Profile)


Sector

Therapeutics

Stage

Development, market readiness, clinical trial

Country

Spain


Opportunity to invest in the clinical development of two novel, well-protected drug candidates for IBD and cancer

OST-122 is a safer IBD medication designed to avoid systemic toxicities inherent in current competitor drugs

OST-499 is the first non-steroidal and therefore safer GR antagonist for the treatment of colorectal cancer

Status

Approved

IP Type

Patent

Time

16 years

Countries

Australia
Austria
Belgium
Canada
China
Denmark
Finland
France
Germany
Israel
Italy
Japan
Netherlands
Russia
South Korea
Spain
Switzerland
USA
United Kingdom

Coverage

“PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS”
The present invention relates to novel 11-oxo-11H-pyrido[2,1 b]quinazoline-6-carboxamide derivatives of formula (I) as potent inhibitors of protein kinase, to pharmaceutical compositions containing them and to the use of said compounds for the manufacture of a drug for the treatment of diseases or pathological diseases that can be improved by inhibiting protein kinase.

Know more of this patent

Status

Pending

IP Type

PCT

Time

Countries

Australia
Austria
Belgium
Canada
China
Denmark
Finland
France
Germany
Israel
Italy
Japan
Netherlands
Russia
South Korea
Spain
Switzerland
USA
United Kingdom

Coverage

“NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS”
The present invention relates to novel dihydropyridine derivatives of formula (I): as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of androgen receptor and/or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases,cachexia, Cushing’s syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.

Know more of this patent

This information is confidential, do not share or copy.

Under evaluation at least till: June 6th, 2022

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2022 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar